Abstract 946
Background
Seasonal influenza vaccination is recommended for cancer patients despite concerns that disease- or treatment-associated immunosuppression may decrease vaccine effectiveness (VE). The objective of this study was to evaluate VE against laboratory-confirmed influenza among cancer patients.
Methods
We conducted an observational test-negative design study of previously diagnosed cancer patients aged ≥18 years who were tested for influenza during the 2010-11 to 2015-16 influenza seasons in Ontario, Canada. We linked individual-level cancer registry, respiratory virus testing, and health administrative data. Vaccination status was determined from physician and pharmacist billing claims. We used multivariable logistic regression to estimate VE, adjusting for age, sex, rurality, neighborhood income, cancer characteristics, chemotherapy exposure, comorbidities, previous healthcare use, influenza season, and calendar time of testing.
Results
We identified 24,668 cancer patients who underwent influenza testing, with 3991 (16%) testing positive and 10,929 (44%) vaccinated. Mean age was 70 years, 52% were male, mean time since cancer diagnosis was 6 years, 79% had a solid tumor malignancy, and 24% were receiving active chemotherapy. The overall adjusted VE (aVE) against laboratory-confirmed influenza was 21% (95%CI, 15%, 27%). The aVE among patients with a solid tumour malignancy was 25% (95%CI, 19%, 31%) as compared with –2% (95%CI, –20%, 14%) amongst patients with a hematologic malignancy (p-value for interaction <0.01). The aVE among patients receiving active chemotherapy was 9% (95%CI, –7%, 23%), compared with 23% (95%CI, 17%, 29%) among patients not on active chemotherapy (p-value for interaction=0.13).
Conclusions
Our results support recommendations for influenza vaccination among cancer patients and survivors. Influenza vaccination appears to be less effective among those undergoing active chemotherapy and we observed uncertain effectiveness among hematologic cancer patients. Strategies to improve VE and influenza vaccine uptake among cancer patients and their families are warranted.
Clinical trial identification
Legal entity responsible for the study
Phillip Blanchette and Jeff Kwong.
Funding
The study was funded by The Canadian Institute for Health Research and Ministry of Health and Long-Term Care in Ontario which provide funding support for Public Health Ontario (PHO) and The Institute of Clinical Evaluative Science (ICES).
Editorial Acknowledgement
Disclosure
K.I. Pritchard: Consultancy: Pfizer, Roche, Amgen, Novartis, Eisai, Genomic Health. A. McGeer: Research funding: Sanofi Pasteur, GlaxoSmithKline. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract